Arima Genomics is shifting its focus toward advancing cancer diagnostics after signing a new distribution partnership with Active Motif Incorporated that will expand access to Arima’s Hi-C genomics technology for research applications.
Under the agreement, Active Motif will hold exclusive distribution rights for Arima’s full portfolio of 3D genomics research kits and services covering non-formalin fixed paraffin embedded (FFPE) sample types, including cell lines, blood, and fresh-frozen tissues.
The partnership will bring Arima’s genomic architecture tools to researchers studying epigenetics, gene regulation, human health and disease, as well as reference-quality genome assembly and haplotype phasing for functional and evolutionary genomics applications.
The deal also marks a strategic move by Arima to concentrate resources on its core clinical diagnostics platform, which uses the company’s proprietary Hi-C sequencing technology to reveal the structural organization of cancer genomes from routine FFPE samples.
That technology powers Arima’s clinical testing portfolio, including Aventa FusionPlus for solid tumors and Aventa Lymphoma, designed to identify actionable fusions and rearrangements that may be overlooked or incompletely characterized by conventional testing approaches.
"We believe the future of cancer diagnostics lies in understanding more of what the genome has to reveal — bringing together DNA sequence and structure to expose the true drivers of disease,” said Tom Willis, CEO of Arima Genomics.
“This agreement allows Arima to focus our resources on advancing that vision through our Aventa clinical diagnostics platform, while ensuring that researchers continue to access these tools through Active Motif’s established commercial infrastructure, complementary product portfolio and deep relationships across the life sciences research community.”
The agreement reinforces Arima’s push to address gaps in current genomic testing methods by combining DNA sequence information with genome structure to uncover clinically relevant cancer alterations.
"Arima has built a differentiated technology platform that is changing how clinically meaningful genomic alterations are detected and understood in cancer,” said Malek Faham, Chief Scientist at Illumina Ventures.
“This agreement sharpens the Company’s focus on the clinical opportunity, where it is well positioned to address important limitations of conventional testing and deliver insights that can inform patient care.”
